Advanced Solid Malignant Tumors Clinical Trial
Official title:
Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors Harboring Either a ROS1 or NTRK Fusion Gene
This is a Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of DS-6051b in Japanese subjects with advanced solid malignant tumors harboring either a ROS1 or NTRK fusion gene.
This study is single arm study with DS-6051b in approximately 9 subjects with advanced solid malignant tumors harboring either a ROS1 or NTRK fusion gene. Safety and tolerability, pharmacokinetics (PK), maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) and preliminary efficacy of DS-6051b will be evaluated. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02192567 -
Open Label Study of DS-5573a
|
Phase 1 | |
Completed |
NCT02690337 -
Study of DS-1123a in Advanced Solid Tumours
|
Phase 1 | |
Completed |
NCT01290471 -
Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors
|
Phase 1 |